A phase II evaluation of fazarabine in high-grade gliomas: a Southwest Oncology Group study.
Selby
G B
GB
University of Oklahoma Health Science Center, Oklahoma City.
Upchurch
C
C
Townsend
J
J
Eyre
H J
HJ
D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001254:Astrocytoma / Q000188:drug therapy; D001374:Azacitidine / Q000009:adverse effects / Q000627:therapeutic use* / Q000031:analogs & derivatives; D001932:Brain Neoplasms / Q000188:drug therapy; D005260:Female; D005909:Glioblastoma / Q000188:drug therapy; D005910:Glioma / Q000188:drug therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D015206:Southwestern United States; D017211:Treatment Failure
D000970:Antineoplastic Agents; C022121:fazarabine; D001374:Azacitidine